Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
A Texas bioidentical-hormone 503B outsourcing facility backed by a PCAB-accredited 503A custom-compounding network spanning HRT, weight loss, and sexual health.
This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.
FarmaKeio spans two entities: a 503B outsourcing facility (Farmakeio Outsourcing LLC, Southlake, TX) that publicly focuses on bioidentical hormone pellets, and a larger 503A custom-compounding network that carries the broader consumer menu.
The 503B (Farmakeio Outsourcing LLC) is on the FDA Registered Outsourcing Facilities list [1], and its own page advertises patented bioidentical hormone pellets delivered to medical practices [2]. The 503A arm — “North American Custom Laboratories, LLC, dba FarmaKeio Superior Custom Compounding” — runs retail/compounding sites (Richardson, TX; Conway, AR; Albuquerque, NM) and says it is licensed in 49 states plus PR and USVI [2]. We independently confirmed PCAB accreditation for the 503A arm in ACHC’s own directory (listed as “North American Custom Labs / FarmaKeio,” Richardson, TX; PCAB Compounding Pharmacy) [3]. Additional badges on the site (IPS, A4PC) are memberships, not independently verified here. FarmaKeio’s 503A entity is also a named plaintiff in the outsourcing-industry (OFA) litigation over the GLP-1 shortage delistings.
The 503B publicly advertises bioidentical hormone pellets [2]. The broader FarmaKeio network markets weight loss, hormone therapy, thyroid/adrenal, and sexual health to providers and patients [2]. Compounded GLP-1 (semaglutide/tirzepatide) is attributed to FarmaKeio by a third-party directory but is not stated on the company’s own 503B page, so we flag GLP-1 as unverified from a primary source.
We found no FDA warning letter or untitled letter for FarmaKeio in public sources. The FDA 503B list shows the Southlake facility with an “Open” action status [1]. (A third-party directory reports a Form 483 around September 2025; we could not locate the FDA primary document, so we don’t assert it.) Dated to our review; status can change.
One of the better-credentialed consumer-facing options here: the 503A arm is PCAB-accredited (independently confirmed via ACHC), the menu covers HRT and weight loss, and no FDA letter is on record. The main nuance is entity structure — the 503B publicly commits only to hormone pellets, so verify exactly which entity fills a given order.